Related Experiment Video
Updated: Sep 11, 2026
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Efficacy and Safety of Patiromer in Hyperkalemia: A Systematic Review and Meta-Analysis
Saibal Das1, Jayanta Kumar Dey1, Sumalya Sen1
11 Department of Pharmacology and Clinical Pharmacology, Christian Medical College, Vellore, Tamil Nadu, India.
Insights
Patiromer effectively lowers potassium levels in patients with hyperkalemia and chronic kidney disease (CKD) or heart failure. However, further trials are needed to confirm its long-term safety and efficacy compared to active treatments.
Area of Science:
- Nephrology
- Cardiology
- Clinical Pharmacology
Background:
- Patients with chronic kidney disease (CKD) stages 3 and 4 face the highest risk of hyperkalemia.
- Hyperkalemia is a serious condition requiring effective management, particularly in patients with co-existing heart failure or CKD.
Purpose of the Study:
- To evaluate the efficacy and safety of patiromer for managing hyperkalemia in patients with heart failure or CKD.
- To synthesize evidence from randomized controlled trials comparing patiromer with placebo or active comparators.
Main Methods:
- A systematic search of the Cochrane Renal Group's Specialized Register was conducted.
- Included were randomized controlled trials assessing patiromer in patients with or at risk of hyperkalemia.
- Primary outcomes included all-cause mortality, hospitalization, hypokalemia/hyperkalemia episodes, and adverse events; secondary outcomes focused on serum potassium changes and other adverse reactions.
Main Results:
- Patiromer demonstrated a significant reduction in serum potassium levels compared to placebo.
- While not significantly improving all-cause mortality or serious cardiovascular events, patiromer showed a significant reduction in non-serious gastrointestinal events.
- Higher doses of patiromer indicated improved efficacy but were associated with increased adverse events.
Conclusions:
- Patiromer shows promise in managing hyperkalemia, particularly in lowering serum potassium.
- Further clinical trials, especially those using active comparators, are essential to fully establish patiromer's role in hyperkalemia treatment.
- The findings suggest a need for careful consideration of dosage and potential adverse events when using patiromer.
Background:
Patients at the highest risk of hyperkalemia are those with chronic kidney disease (CKD) stages 3 and 4.
Objective:
To evaluate the efficacy and safety of patiromer in hyperkalemia in patients with heart failure or CKD.
Methods:
The Cochrane Renal Group's Specialized Register was searched through contact with the Trials' Search Coordinator. We aimed at including randomized controlled trials with patiromer in patients with developed or risks of developing hyperkalemia, comparing against an active comparator or placebo. Three studies matched our inclusion and exclusion criteria, which we included in the meta-analysis. All-cause mortality, reduction in hospitalization, episodes of hypokalemia or hyperkalemia, and cardiovascular and gastrointestinal adverse events during the treatment period were our primary outcomes. Serial change in serum potassium (K+) until end of treatment or follow-up during the trial period and all other reported adverse reactions during the treatment period were our secondary outcomes. Meta-analysis (RevMan version 5.3.5) and descriptive statistics were used.
Results:
There was a non-significant improvement in all-cause mortality and serious cardiovascular events with patiromer than placebo. Hospitalization data were unavailable. Although serious gastrointestinal events were more common with placebo, there was a significant reduction ( P = .02) in the risk of non-serious gastrointestinal events with placebo. Patiromer lowered serum K+ more than placebo, and there were more patients developing hyperkalemia with placebo. High-dose patiromer was associated with better efficacy in some parameters but with more adverse events.
Conclusion:
Although patiromer seems promising, more trials with active comparator are essential to finalize its indication and use in hyperkalemia.
Related Concept Videos
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:26Heart Failure Drugs: Inotropic Agents
01:22Heart Failure Drugs: Diuretics
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions